Author

J. M. Vahrenkamp

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 7

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 7 Approach:experimental assay· 5 Research Focus:cell type annotation· 4 Assay:ChIP-seq· 4 Research Focus:differential expression· 4 Assay:bulk RNA-seq· 3 Research Focus:chromatin & epigenetic regulation· 3 Approach:genetic perturbation / CRISPR· 3

Frequent Co-Authors

J. Gertz· 7 shared C.-H. Yang· 3 shared D. H. Lum· 3 shared Z. Blanchard· 3 shared A. C. Rodriguez· 2 shared B. E. Welm· 2 shared C. M. Rush· 2 shared E. A. Jarboe· 2 shared

Activity by Year

2018-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

7 shared papersCancer Biology

J. Gertz

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

ASPSCR1-TFE3 reprograms transcription by organizing enhancer loops around hexameric VCP/p97

A. Pozner, S. P. Verma, L. Li, S. Wang, J. J. Barrott, M. L. Nelson, J. S. E. Yu, G. L. Negri, S. Colborne, C. S. Hughes, J.-F. Zhu, S. L. Lambert, L. S. Carroll, K. Smith-Fry, M. G. Stewart, , K. B. Jones

This study identifies VCP/p97 as an obligate co-factor of ASPSCR1-TFE3, showing it organizes enhancer loops to drive oncogenic transcription in ASPS and RCC.

bioRxiv · Sep 29, 2023Cancer Biology

Characterization of a novel estrogen- and progesterone-responsive endometrial cancer cell line: HCI-EC-23

C. M. Rush, Z. Blanchard, J. T. Polaski, K. S. Osborne, K. Osby, J. M. Vahrenkamp, C.-H. Yang, D. H. Lum, C. R. Hagan, K. K. Leslie, M. A. Pufall, K. W. Thiel, J. Gertz

This paper introduces a new endometrial cancer cell line, HCI-EC-23, which responds to estrogen and progesterone, and shows it has similar estrogen-responsive gene regulation to Ishikawa cells.

bioRxiv · Aug 25, 2022Cancer Biology

TXNIP loss expands Myc-dependent transcriptional programs by increasing Myc genomic binding

T.-Y. Lim, B. R. Wilde, M. L. Thomas, K. E. Murphy, J. M. Vahrenkamp, M. E. Conway, K. E. Varley, J. Gertz, D. E. Ayer

This study shows that TXNIP loss increases Myc genomic binding, expanding Myc-dependent transcriptional programs without increasing Myc levels or activity.

bioRxiv · Aug 4, 2022 · PreprintCancer Biology

Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer

Z. Blanchard, C. M. Rush, S. Arnesen, J. M. Vahrenkamp, A. C. Rodriguez, E. A. Jarboe, C. Brown, M. E. K. Chang, M. R. Flory, H. Mohammed, K. Modzelewska, D. H. Lum, J. Gertz

This study investigates ER mutations in endometrial cancer, showing they alter gene expression and promote cancer phenotypes, and identifies potential therapeutic targets.

bioRxiv · Jun 13, 2022Cancer Biology

A breast cancer patient-derived xenograft and organoid platform for drug discovery and precision oncology

K. P. Guillen, M. Fujita, A. J. Butterfield, S. D. Scherer, M. H. Bailey, Z. Chu, Y. S. DeRose, L. Zhao, E. Cortes-Sanchez, C.-H. Yang, J. Toner, G. Wang, Y. Qiao, X. Huang, J. A. Greenland, , A. L. Welm

The paper develops patient-derived xenografts and organoids for breast cancer to enable drug screening and precision oncology, showing efficacy of an FDA-approved drug in a clinical case.

bioRxiv · Feb 28, 2021 · PreprintCancer Biology

Estrogen-independent molecular actions of mutant estrogen receptor alpha in endometrial cancer

Z. Blanchard, J. M. Vahrenkamp, K. C. Berrett, S. Arnesen, J. Gertz

This study investigates estrogen-independent actions of the D538G ESR1 mutation in endometrial cancer, showing altered genomic binding, gene expression, and chromatin accessibility compared to wildtype ESR1.

bioRxiv · Jul 3, 2019Cancer Biology

Clinical and genomic crosstalk between glucocorticoid receptor and estrogen receptor α in endometrial cancer

J. M. Vahrenkamp, C.-H. Yang, A. C. Rodriguez, A. Almomen, K. Berrett, A. N. Trujillo, K. P. Guillen, B. E. Welm, E. A. Jarboe, M. M. Janat-Amsbury, J. Gertz

The paper investigates the interaction between glucocorticoid receptor (GR) and estrogen receptor α (ER) in endometrial cancer, finding that GR expression correlates with poor prognosis and that their combined activity alters gene expression and genomic binding.

bioRxiv · Mar 7, 2018Cancer Biology